Double‐Blind, Placebo‐Controlled Evaluation of Cinromide in Patients with the Lennox‐Gastaut Syndrome
- 1 August 1989
- Vol. 30 (4) , 422-429
- https://doi.org/10.1111/j.1528-1157.1989.tb05321.x
Abstract
This study evalauted the effects of of cinromide in patients with Lennox-Gastaut Syndrome. No difference between cinromide and placebo was shown in terms of seizure reduction or global evaluations. This study is important, however, because it represents an effort to overcome methodologic difficulties inherent in evaluating this population, and because a substantial placebo response was demonstrated. The need for well-designed, placebo-controlled clinical studies of potential antiepileptic drugs, even in an especially refractory and mentally impaired population, is underscored by the study''s outcome.Keywords
This publication has 6 references indexed in Scilit:
- Experimental Anticonvulsant Cinromide in Monkey Model: Preliminary EfficacyEpilepsia, 1979
- Simultaneous determination of the anticonvulsants, cinromide (3-bromo-N-ethylcinnamamide), 3-bromocinnamamide, and carbamazepine in plasma by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1979
- Childhood Epileptic Encephalopathy with Diffuse Slow Spike‐Waves (otherwise known as “Petit Mal Variant”) or Lennox SyndromeEpilepsia, 1966
- CLINICAL CORRELATES OF THE FAST AND THE SLOW SPIKE-WAVE ELECTROENCEPHALOGRAMPediatrics, 1950
- THE PETIT MAL EPILEPSIESJAMA, 1945
- MEMBERS OF THE AMERICAN CHAPTER OF THE INTERNATIONAL LEAGUE AGAINST EPILEPSY. September 1, 1944Epilepsia, 1944